{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:08:05Z","timestamp":1791216485244,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2015,7,16]],"date-time":"2015-07-16T00:00:00Z","timestamp":1437004800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1007\/s40261-015-0309-3","type":"journal-article","created":{"date-parts":[[2015,7,15]],"date-time":"2015-07-15T12:00:27Z","timestamp":1436961627000},"page":"525-529","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Bromfenac Ophthalmic Solution 0.07\u00a0%: A Review of Its Use After Cataract Surgery"],"prefix":"10.1007","volume":"35","author":[{"given":"Sheridan M.","family":"Hoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,7,16]]},"reference":[{"issue":"1","key":"309_CR1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/00055735-200102000-00002","volume":"12","author":"SM El-Harazi","year":"2001","unstructured":"El-Harazi SM, Feldman RM. Control of intra-ocular inflammation associated with cataract surgery. Curr Opin Ophthalmol. 2001;12(1):4\u20138.","journal-title":"Curr Opin Ophthalmol."},{"issue":"2","key":"309_CR2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.17925\/EOR.2012.06.02.98","volume":"6","author":"HS Dua","year":"2012","unstructured":"Dua HS, Attre R. Treatment of post-operative inflammation following cataract surgery: a review. European Ophthalmic Review. 2012;6(2):98\u2013103.","journal-title":"European Ophthalmic Review."},{"key":"309_CR3","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2147\/PPA.S46667","volume":"8","author":"RK Rajpal","year":"2014","unstructured":"Rajpal RK, Ross B, Rajpal SD, et al. Bromfenac ophthalmic solution for the treatment of postoperative ocular pain and inflammation: safety, efficacy, and patient adherence. Patient Prefer Adherence. 2014;8:925\u201331.","journal-title":"Patient Prefer Adherence."},{"key":"309_CR4","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.2147\/OPTH.S66638","volume":"8","author":"GA Baklayan","year":"2014","unstructured":"Baklayan GA, Mu\u00f1oz M. The ocular distribution of 14C-labeled bromfenac ophthalmic solution 0.07 % in a rabbit model. Clin Ophthalmol. 2014;8:1717\u201324.","journal-title":"Clin Ophthalmol."},{"issue":"2","key":"309_CR5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1208\/s12248-008-9024-9","volume":"10","author":"M Ahuja","year":"2008","unstructured":"Ahuja M, Dhake AS, Sharma SK, et al. Topical ocular delivery of NSAIDs. AAPS J. 2008;10(2):229\u201341.","journal-title":"AAPS J."},{"key":"309_CR6","unstructured":"ISTA Pharmaceuticals Inc. Bromday (bromfenac ophthalmic solution) 0.09 %: US prescribing information. 2010. http:\/\/www.fda.gov\/ . Accessed 22 Jun 2015."},{"key":"309_CR7","unstructured":"Bausch & Lomb Inc. PROLENSA\u2122 (bromfenac ophthalmic solution) 0.07 %: US prescribing information. 2013. http:\/\/www.fda.gov\/ . Accessed 22 Jun 2015."},{"key":"309_CR8","author":"SD Schoenberger","year":"2013","unstructured":"Schoenberger SD, Kim SJ. Nonsteroidal anti-inflammatory drugs for retinal disease. Int J Inflam. 2013. doi: 10.1155\/2013\/281981","journal-title":"Int J Inflam."},{"issue":"5","key":"309_CR9","doi-asserted-by":"crossref","first-page":"e96481","DOI":"10.1371\/journal.pone.0096481","volume":"9","author":"T Kida","year":"2014","unstructured":"Kida T, Kozai S, Takahashi H, et al. Pharmacokinetics and efficacy of topically applied nonsteroidal anti-inflammatory drugs in retinochoroidal tissues in rabbits. PLoS ONE. 2014;9(5):e96481.","journal-title":"PLoS ONE."},{"issue":"2","key":"309_CR10","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/BF00126444","volume":"7","author":"J Ruiz","year":"1993","unstructured":"Ruiz J, L\u00f3pez M, Mil\u00e0 J, et al. QSAR and conformational analysis of the antiinflammatory agent amfenac and analogues. J Comput Aided Mol Des. 1993;7(2):183\u201398.","journal-title":"J Comput Aided Mol Des."},{"issue":"5","key":"309_CR11","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/ICO.0000000000000309","volume":"34","author":"DD Singer","year":"2015","unstructured":"Singer DD, Kennedy J, Wittpenn JR. Topical NSAIDs effect on corneal sensitivity. Cornea. 2015;34(5):541\u20133.","journal-title":"Cornea."},{"key":"309_CR12","unstructured":"Geneva II, Henderson BA. Prospective interventional pilot study using bromfenac 0.07 % after cataract surgery for prevention of macular thickening. In: American Society of Cataract and Refractive Surgery & American Society of Ophthalmic Administrators Symposium & Congress (ASCRS). Boston, MA. 2014."},{"key":"309_CR13","unstructured":"Data on file, Bausch & Lomb Inc, 2015."},{"issue":"1","key":"309_CR14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ophtha.2013.07.006","volume":"121","author":"TR Walters","year":"2014","unstructured":"Walters TR, Goldberg DF, Peace JH, et al. Bromfenac ophthalmic solution 0.07 % dosed once daily for cataract surgery: results of 2 randomized controlled trials. Ophthalmology. 2014;121(1):25\u201333.","journal-title":"Ophthalmology."},{"key":"309_CR15","unstructured":"US FDA. Center for Drug Evaluation and Research application number 203168Orig1s000: summary review. 2013. http:\/\/www.fda.gov\/ . Accessed 22 Jun 2015."},{"key":"309_CR16","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2147\/OPTH.S60292","volume":"8","author":"SM Silverstein","year":"2014","unstructured":"Silverstein SM, Jackson MA, Goldberg DF, et al. The efficacy of bromfenac ophthalmic solution 0.07 % dosed once daily in achieving zero-to-trace anterior chamber cell severity following cataract surgery. Clin Ophthalmol. 2014;8:965\u201372.","journal-title":"Clin Ophthalmol."},{"key":"309_CR17","unstructured":"Health Canada. Summary basis of decision (SBD) for Prolensa. 2015. http:\/\/www.hc-sc.gc.ca\/ . Accessed 22 Jun 2015."},{"issue":"4","key":"309_CR18","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/pds.1207","volume":"15","author":"L Goldkind","year":"2006","unstructured":"Goldkind L, Laine L. A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience. Pharmacoepidemiol Drug Saf. 2006;15(4):213\u201320.","journal-title":"Pharmacoepidemiol Drug Saf."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-015-0309-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-015-0309-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-015-0309-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T19:28:55Z","timestamp":1559503735000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-015-0309-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,16]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["309"],"URL":"https:\/\/doi.org\/10.1007\/s40261-015-0309-3","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,16]]}}}